FMP

FMP

Enter

AZN - AstraZeneca PLC

photo-url-https://images.financialmodelingprep.com/symbol/AZN.png

AstraZeneca PLC

AZN

NASDAQ

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

67.57 USD

0.27 (0.4%)

Operating Data

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

26.62B

37.42B

44.35B

45.81B

54.07B

64.95B

78.01B

93.69B

112.53B

135.16B

Revenue %

-

40.58

18.53

3.29

18.03

20.11

20.11

20.11

20.11

Ebitda

8.08B

5.11B

9.09B

13.91B

15.44B

16.03B

19.26B

23.13B

27.78B

33.37B

Ebitda %

30.37

13.66

20.48

30.37

28.55

24.69

24.69

24.69

24.69

Ebit

5.19B

1.01B

3.83B

8.98B

10.37B

9.04B

10.86B

13.04B

15.67B

18.82B

Ebit %

19.49

2.7

8.64

19.6

19.18

13.92

13.92

13.92

13.92

Depreciation

2.9B

4.1B

5.25B

4.93B

5.07B

6.99B

8.4B

10.09B

12.11B

14.55B

Depreciation %

10.88

10.96

11.85

10.77

9.37

10.77

10.77

10.77

10.77

Balance Sheet

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Total Cash

7.99B

6.4B

6.41B

5.86B

5.65B

11.02B

13.23B

15.89B

19.09B

22.93B

Total Cash %

30.03

17.1

14.44

12.79

10.46

16.96

16.96

16.96

16.96

Receivables

3.81B

6.03B

7.21B

8.41B

11.23B

11.15B

13.39B

16.08B

19.31B

23.2B

Receivables %

14.3

16.12

16.26

18.35

20.78

17.16

17.16

17.16

17.16

Inventories

4.02B

8.98B

4.7B

5.42B

5.29B

9.27B

11.13B

13.37B

16.06B

19.28B

Inventories %

15.12

24.01

10.6

11.84

9.78

14.27

14.27

14.27

14.27

Payable

2.35B

2.82B

2.55B

3.27B

3.64B

4.67B

5.61B

6.74B

8.1B

9.73B

Payable %

8.83

7.55

5.75

7.13

6.73

7.2

7.2

7.2

7.2

Cap Ex

-2.61B

-2.2B

-2.57B

-3.78B

-4.59B

-4.96B

-5.96B

-7.16B

-8.6B

-10.33B

Cap Ex %

-9.79

-5.88

-5.8

-8.25

-8.48

-7.64

-7.64

-7.64

-7.64

Weighted Average Cost Of Capital

Price

67.57

Beta

Diluted Shares Outstanding

12.5B

Costof Debt

5.59

Tax Rate

After Tax Cost Of Debt

4.52

Risk Free Rate

Market Risk Premium

Cost Of Equity

Total Debt

30.11B

Total Equity

844.9B

Total Capital

875.01B

Debt Weighting

3.44

Equity Weighting

96.56

Wacc

4.91

Build Up Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

26.62B

37.42B

44.35B

45.81B

54.07B

64.95B

78.01B

93.69B

112.53B

135.16B

Ebitda

8.08B

5.11B

9.09B

13.91B

15.44B

16.03B

19.26B

23.13B

27.78B

33.37B

Ebit

5.19B

1.01B

3.83B

8.98B

10.37B

9.04B

10.86B

13.04B

15.67B

18.82B

Tax Rate

19.05

19.05

19.05

19.05

19.05

19.05

19.05

19.05

19.05

19.05

Ebiat

4.23B

-427.29M

5.04B

7.75B

8.4B

6.31B

7.58B

9.1B

10.93B

13.13B

Depreciation

2.9B

4.1B

5.25B

4.93B

5.07B

6.99B

8.4B

10.09B

12.11B

14.55B

Receivables

3.81B

6.03B

7.21B

8.41B

11.23B

11.15B

13.39B

16.08B

19.31B

23.2B

Inventories

4.02B

8.98B

4.7B

5.42B

5.29B

9.27B

11.13B

13.37B

16.06B

19.28B

Payable

2.35B

2.82B

2.55B

3.27B

3.64B

4.67B

5.61B

6.74B

8.1B

9.73B

Cap Ex

-2.61B

-2.2B

-2.57B

-3.78B

-4.59B

-4.96B

-5.96B

-7.16B

-8.6B

-10.33B

Ufcf

-955.87M

-5.24B

10.55B

7.7B

6.56B

5.48B

6.85B

8.23B

9.88B

11.87B

Wacc

4.91

4.91

4.91

4.91

4.91

Pv Ufcf

5.23B

6.23B

7.13B

8.16B

9.34B

Sum Pv Ufcf

36.09B

Terminal Value

Growth In Perpetuity Method

Long Term Growth Rate

Wacc

4.91

Free Cash Flow T1

12.11B

Terminal Value

416.43B

Present Terminal Value

327.72B

Intrinsic Value

Enterprise Value

363.81B

Net Debt

24.63B

Equity Value

339.18B

Diluted Shares Outstanding

12.5B

Equity Value Per Share

27.13

Projected DCF

27.13 -1.491%

DCF Levered

Download Excel

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep